Lantheus Holdings, Inc.

Health Care
Biotechnology: In Vitro & In Vivo Diagnostic Substances
www.lantheus.com

Earnings Score
Moat Score
Safety Score

Market Cap $6.15B
PE 14
Debt $1.13B
Cash $868.05M
EV $6.42B
FCF $418.40M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	$427.61M
EBIT	$570.16M
ROE	36%
ROA	28%
FCF	$418.40M
Equity	$1.18B
Growth Stability	-364%
PE	14.39
PEG	0.18
PB	5.22
P/FCF	14.71
P/S	4.11
Price/Cash	0.14
Debt/Equity	0.96
Debt/FCF	2.7
Net Margins	28%
Gross Margins	65%
Op. Margins	38%
Earnings CAGR	9%
Sales Growth YoY	18%
Sales Growth QoQ	-4%
Sales CAGR	20%
FCF CAGR	19%
Equity CAGR	53%
Earnings Stability	0.06
Earnings Growth YoY	-1%
Earnings Growth QoQ	111%

Earnings CAGR 5Y	78%
Sales CAGR 5Y	47%
FCF CAGR 5Y	68%
Equity CAGR 5Y	35%
Earnings CAGR 3Y	54%
Sales CAGR 3Y	54%
FCF CAGR 3Y	111%
Equity CAGR 3Y	38%
Market Cap	$6.15B
Revenue	$1.50B
Assets	$2.05B
Total Debt	$1.13B
Cash	$868.05M
Shares Outstanding	69.13M
EV	6.42B
Earnings Score	7%
Moat Score	97%
Safety Score	59%
Final Score	54%
Working Capital	511.64M
Current Ratio	1.65
Gross Profit	$969.62M
Shares Growth 3y	1%
Equity Growth QoQ	15%
Equity Growth YoY	69%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its imaging products and agents assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its agents are typically non-radioactive compounds that are used in diagnostic procedures, such as cardiac ultrasounds, or echocardiograms, x-ray imaging used by physicians to progress the clarity of the diagnostic image. Its portfolio of imaging products includes medical radiopharmaceuticals such as DEFINITY, TechneLite, Xenon Xe 133 Gas, Cardiolite, and Neurolite. Its revenue is generated from the sales of diagnostic imaging agents to wholesalers, distributors radiopharmacy and directly to hospitals and clinics predominantly in the United States.

SEC Filings

Direct access to Lantheus Holdings, Inc. (LNTH) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Lantheus Holdings, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Lantheus Holdings, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 9%

Stability 6%

loading chart...

Lantheus Holdings, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Lantheus Holdings, Inc..

Years

Calculation mode

= $16B

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$418M	$498M	$593M	$706M	$840M	$1B	$1.2B	$1.4B	$1.7B	$2B	$2.4B	$24B
DCF		$453M	$490M	$530M	$574M	$621M	$672M	$728M	$788M	$852M	$923M	$9.2B
Value	$16B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	-1%	-5%	9%	37%	12%	9%	-4%	-17%	3%	25%	28%
ROA	-	18%	22%	15%	15%	13%	-0%	-7%	3%	25%	28%
ROE	-	8%	-25%	530%	57%	28%	-3%	-15%	6%	40%	36%

Good Net Margins (28.37%)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	41.05	6.58	7.2	6.49	3.52	60.96	4.47	26.42	2.22	2.7
Debt over Equity	-1.64	-1.91	-2.61	11.51	3.75	1.79	0.46	0.4	1.29	0.71	0.96
Growth Stability	-	-	-	100%	90%	50%	-21%	-364%	-	-	-364%

Neutral Debt/FCF ratio (2.7)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Good Debt/Equity ratio (0.96)

The company is not overleveraged and has a good balance between equity and debt.

Bad Graham’s Stability (-364%)

The company has a bad stability in its earnings, which is a sign of a bad competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	-3%	3%	10%	4%	1%	-2%	25%	120%	39%	47%
Earnings YoY growth	-	314%	-281%	361%	-67%	-22%	-143%	429%	-139%	1K%	78%
Equity YoY growth	-	-23%	-43%	-122%	205%	61%	349%	-10%	-4%	82%	35%
FCF YoY growth	-	149%	391%	-12%	10%	42%	-93%	965%	-48%	1K%	68%